{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:39:01Z","timestamp":1787027941238,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Przemyslaw Zdziarski","award":["501-15"],"award-info":[{"award-number":["501-15"]}]},{"name":"statutory activity of Hirszfeld Institute","award":["501-15"],"award-info":[{"award-number":["501-15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Although lymphoma is the most frequent malignancy in common variable immunodeficiency (CVID), solid tumors, especially affected by oncogenic viruses, are not considered. Furthermore, in vitro genetic studies and cell cultures are not adequate for immune system and HBV interaction. We adopted a previously introduced clinical model of host\u2013virus interaction (i.e., infectious process in immunodeficiency) for analysis of B cells and the specific IgG role (an observational study of a CVID patient who received intravenous immunoglobulin (IVIG). Suddenly, the patient deteriorated and a positive results of for HBs and HBV-DNA (369 \u00d7 106 copies) were detected. Despite lamivudine therapy and IVIG escalation (from 0.3 to 0.4 g\/kg), CT showed an 11 cm intrahepatic tumor (hepatocellular carcinoma). Anti-HBs were positive in time-lapse analysis (range 111\u2013220 IU\/mL). Replacement therapy intensification was complicated by an immune complex disease with renal failure. Fulminant HCC in CVID and the development of a tumor as the first sign is of interest. Unfortunately, treatment with hepatitis B immune globulins (HBIG) plays a major role in posttransplant maintenance therapy. Anti-HB substitution has not been proven to be effective, oncoprotective, nor safe. Therefore, immunosuppression in HBV-infected recipients should be carefully minimized, and patient selection more precise with the exclusion of HBV-positive donors. Our clinical model showed an HCC pathway with important humoral host factors, contrary to epidemiological\/cohort studies highlighting risk factors only (e.g., chronic hepatitis). The lack of cell cooperation as well as B cell deficiency observed in CVID play a crucial role in high HBV replication, especially in carcinogenesis.<\/jats:p>","DOI":"10.3390\/diseases12050080","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T03:20:41Z","timestamp":1713842441000},"page":"80","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of B Cells beyond Antibodies in HBV-Induced Oncogenesis: Fulminant Cancer in Common Variable Immunodeficiency\u2014Clinical and Immunotransplant Implications with a Review of the Literature"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5692-4734","authenticated-orcid":false,"given":"Przemyslaw","family":"Zdziarski","sequence":"first","affiliation":[{"name":"Lower Silesian Center for Cellular Transplantation, 53-439 Wroclaw, Poland"},{"name":"Clinical Research Center PRION, 50-385 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-6591","authenticated-orcid":false,"given":"Andrzej","family":"Gamian","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.vaccine.2004.11.057","article-title":"Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose","volume":"23","author":"Fonseca","year":"2005","journal-title":"Vaccine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1197361","DOI":"10.3389\/fimmu.2023.1197361","article-title":"Clinical manifestations and approach to the management of patients with common variable immunodeficiency and liver disease","volume":"14","author":"Camara","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13223-017-0213-x","article-title":"Passive blood anaphylaxis: Subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction","volume":"13","author":"Zdziarski","year":"2017","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1056\/NEJMcpc1408595","article-title":"Case 41-2015. A 14-Year-Old Boy with Immune and Liver Abnormalities","volume":"373","author":"Walter","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rizzo, G.E.M., Cabibbo, G., and Crax\u00ec, A. (2022). Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses, 14.","DOI":"10.3390\/v14050986"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zdziarski, P. (2019). CMV-Specific Immune Response-New Patients, New Insight: Central Role of Specific IgG during Infancy and Long-Lasting Immune Deficiency after Allogenic Stem Cell Transplantation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020271"},{"key":"ref_7","unstructured":"(2023, January 20). Saleem Kamili Laboratory Procedure Manual Analyte: Hepatitis B Surface Antibody (Anti-HBS) CDC September, 2013. Hepatitis B Surface Antibody (Anti-HBS)\u2014CDC, Available online: https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/2007-2008\/labmethods\/hepb_s_e_met_hep_b_surface_antibody.pdf."},{"key":"ref_8","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1542\/peds.90.1.170","article-title":"Prospects for control of hepatitis B virus infection: Implications of childhood vaccination and long-term protection","volume":"90","author":"Stevens","year":"1992","journal-title":"Pediatrics"},{"key":"ref_10","unstructured":"Hollinger, F.B., Lemon, S.M., and Margolis, H. (1991). Viral Hepatitis and Liver Disease: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease, Williams & Wilkins."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2893.2003.00400.x","article-title":"Hepatitis B vaccine\u2014Do we need boosters?","volume":"10","author":"Banatvala","year":"2003","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/01.TP.0000047030.38665.0D","article-title":"Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantation","volume":"75","author":"Hwang","year":"2003","journal-title":"Transplantation"},{"key":"ref_13","first-page":"392","article-title":"\u03b22-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system","volume":"136","author":"Ardeniz","year":"2015","journal-title":"JACI"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1130899","DOI":"10.3389\/fonc.2023.1130899","article-title":"Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21","volume":"13","author":"Giordano","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_15","first-page":"78","article-title":"Importance of the Tumor Boards\u2019 decisions for the patientcentered care\u2014Case studies in the COVID-19 era","volume":"50","author":"Zdziarski","year":"2022","journal-title":"Pol. Merkur. Lekarski."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1016\/j.transproceed.2009.09.083","article-title":"Evaluation of Anti-HBs serum levels and pharmacokinetic profile after intravenous administration of Niuliva, a new hepatitis B immunoglobulin, following liver transplantation","volume":"41","author":"Mas","year":"2009","journal-title":"Transplant. Proc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/lt.22354","article-title":"Hepatitis B immunoglobulin and\/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: A systematic review","volume":"17","author":"Cholongitas","year":"2011","journal-title":"Liver Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.12659\/AOT.910176","article-title":"Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis","volume":"23","author":"Beckebaum","year":"2018","journal-title":"Ann. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/gut.50.1.95","article-title":"Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors","volume":"50","author":"Feray","year":"2002","journal-title":"Gut"},{"key":"ref_20","first-page":"501","article-title":"Acute renal failure following intravenous administration of hepatitis B im-munoglobulin in liver transplantation","volume":"55","author":"Donataccio","year":"2009","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1567-5769(01)00019-4","article-title":"Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4","volume":"1","author":"Blanchong","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1031291","DOI":"10.3389\/fimmu.2022.1031291","article-title":"Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers\u2014A prospective cohort study of 417 cases","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Guo, Y., Liu, J., Meng, L., Meina, H., and Du, Y. (2010). Survey of HBsAg-positive pregnant women and their infants regarding measures to prevent maternal-infantile transmission. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-26"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/HMER.S13796","article-title":"Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection","volume":"2","author":"Mukherjee","year":"2010","journal-title":"Hepat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1036612","DOI":"10.3389\/fimmu.2022.1036612","article-title":"Cytokine profiles CD8+ T cells in the occurrence of acute chronic hepatitis, B","volume":"13","author":"Xie","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1083862","DOI":"10.3389\/fimmu.2022.1083862","article-title":"A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","article-title":"The EUROclass trial: Defining subgroups in common variable immunodeficiency","volume":"111","author":"Wehr","year":"2008","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/23744235.2019.1693624","article-title":"Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy","volume":"52","author":"Buonomo","year":"2020","journal-title":"Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-022-29450-x","article-title":"Single-cell Atlas of common variable immunodeficiency shows germinal center-associated epigenetic dysregulation in B-cell responses","volume":"13","author":"Arutyunyan","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1084\/jem.182.3.801","article-title":"Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: Regulation upon CD16 ligand binding","volume":"182","author":"Aramburu","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3748\/wjg.v13.i1.74","article-title":"Hepatitis B virus-induced oncogenesis","volume":"13","author":"Lupberger","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_33","first-page":"297","article-title":"Cellular transplantation\u2013orthotopic liver transplantation alternative","volume":"23","author":"Zdziarski","year":"2007","journal-title":"Pol. Merkur. Lekarski."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1264482","DOI":"10.3389\/fimmu.2023.1264482","article-title":"Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: A case report and literature study","volume":"14","author":"Roosens","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3389\/fphar.2018.01559","article-title":"Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency\u2014Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens","volume":"9","author":"Zdziarski","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.clinre.2019.07.002","article-title":"Common variable immunodeficiency and chronic hepatitis B: Therapeutic challenge","volume":"44","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/5\/80\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:32:26Z","timestamp":1760106746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/5\/80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["diseases12050080"],"URL":"https:\/\/doi.org\/10.3390\/diseases12050080","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}